Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Radical -xh acid – or anhydride – acid halide or salt thereof...
Reexamination Certificate
1998-08-12
2002-09-03
Cook, Rebecca (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Radical -xh acid, or anhydride, acid halide or salt thereof...
C514S058000
Reexamination Certificate
active
06444703
ABSTRACT:
TECHNICAL FIELD
The present invention provides a pharmaceutical composition which is effective for eradication
Helicobacter pylori
living in human stomach and, accordingly, said invention is utilized in the medical field.
The present invention also provides a complex of 4-[4-(4-methylbenzyloxycarbonyl)phenyl]phenyl trans-4-guanidinomethylcyclohexanecarboxylate or an acid addition salt thereof with &bgr;-cyclodextrin.
BACKGROUND ART
Helicobacter pylori
is a bacterium which has recently attached considerable attention in view of its relationship with diseases of digestive organs. It has become an important factor to be taken into consideration especially when diseases, particularly ulcer, of stomach and duodenum is investigated.
As the drugs effective for inhibiting the growth of
Helicobacter pylori
antibiotic substances such as ampicillin, amoxicillin, caphalexin and clarithromycin and synthetic antibacterials such as ofloxacin and ciprofloxacin have been known. It has been clarified that
Helicobacter pylori
has participated in recurrence of ulcer and, at the same time, prevention of recurrence of ulcer by a combined use of those antibacterials with antiulcer agent has been investigated.
Incidentally, when anitiobiotics or synthetic antibacterials are administered, they are absorbed from digestive organs into blood and arrive at the diseased site to achieve the effect while some of them are excreted after passing through the digestive organs and, when the drug passes through the intestinal tract, many bacteria living in intestine are killed whereby enterobacterial fleora is unbalanced. Accordingly, administration of such a drug for long term is to be avoided.
Since
Helicobacter pylori
is a bacterium living in stomach, there has been a demand for a compound having a property that its activity to said bacterium is effectively achieved in stomach and, after that, the antibacterial activity decreases when it moves to duodenum and then to small intestine and finally said activity disappears. Incidentally, there is a compound whose generic name is benexate hydrochloride and it has been known that said compound has an anti-
Helicobacter pylori
activity with MICs ranging from 25 to 50 &mgr;g/ml (“Diseases of Digestive Organs and
Helicobacter pylori
”, page 91; published by Medical Review).
The present applicant previously found a compound showing an effective antibacterial activity which is specific to
Helicobacter pylori
although it was a result of the test in vitro (WO 96/06825) and, in view of the fact that the result in vivo does not always coincide with that in vitro. The mode of its use was investigated whereby the present invention has been achieved.
DISCLOSURE OF THE INVENTION
The present invention is to provide a composition of 4-[4-(4-methylbenzyloxycarbonyl)phenyl]phenyl trans-4-guanidinomethylcyclohexanecarboxylate or an acid addition salt thereof (hereinafter, it will be referred to as “the present compound”) which is suitable for exterminating or eradicating
Helicobacter pylori
in living body by the use of the present compound.
It has been known that, although the present compound exhibits an antibacterial action quite specifically to
Helicobacter pylori
according to an in vitro test (WO 96/06825), such an antibacterial activity in vitro is not available in an in vivo test as it is. As one of the causes, we took the solubility of the present compound into consideration but, after various investigations, it has been found that an improvement in solubility only is not able to afford the effect of eradication or extermination of
Helicobacter pylori
and, at the same time, we have found that a combined use of the present compound with cyclodextrin, particularly with &bgr;-cyclodextrin, is effective in eradication or extermination of
Helicobacter pylori
in living body whereupon the present invention has been achieved.
The present invention provides a pharmaceutical composition having an anti-
Helicobacter pylori
action which contains 4-[4-(4-methylbenzyloxycarbonyl)phenyl]phenyl trans-4-guanidinomethylcyclohexanecarboxylate or an acid addition salt thereof and &bgr;-cyclodextrin.
The present invention also provides a complex of 4-[4- (4-methyl-benzyloxycarbonyl)phenyl]phenyl trans-4-guanidinomethylcyclohexanecarboxylate or an acid addition salt thereof with &bgr;-cyclodextrin.
The composite which is an object of the present invention is also an effective component of the pharmaceutical composition of the present invention and it consists of the present compound and &bgr;-cyclodextrin and may be prepared by grinding the two substances or by making them an aqueous solution followed by subjecting to a treatment of spray-drying, freeze-drying or drying by means of concentration.
Further, even In the case where they are just mixed, it is effective in eradication or extermination of
Helicobacter pylori
which is an object of the present invention provided that said mixture is dissolved in water. Therefore, such a mixture is covered by the present invention as well.
Accordingly, the present invention provides a mixture or a complex (inclusion compound) of 4-[4-(4-methylbenzyloxycarbonyl)phenyl]phenyl trans-4-guanidinomethylcyclohexane carboxylate or an acid addition salt thereof and &bgr;-cyclodextrin and also offers a composition containing the same which has an anti-
Helicobacter pylori
action.
REFERENCES:
patent: 078 599 (1983-05-01), None
patent: 0 585 130 (1994-03-01), None
patent: 0 775 692 (1997-05-01), None
patent: 45454/81 (1981-04-01), None
patent: 92260/81 (1981-07-01), None
patent: 92261/81 (1981-07-01), None
patent: 16855/82 (1982-01-01), None
patent: 16856/82 (1982-01-01), None
patent: 21360/82 (1982-02-01), None
patent: 75921/82 (1982-02-01), None
patent: 48958/82 (1982-03-01), None
patent: 48959/82 (1982-03-01), None
patent: 48960/82 (1982-03-01), None
patent: 75920/82 (1982-05-01), None
patent: 75922/82 (1982-05-01), None
patent: 35556/82 (1982-07-01), None
patent: 122059/82 (1982-07-01), None
patent: 122060/82 (1982-07-01), None
patent: 122061/82 (1982-07-01), None
patent: 122062/82 (1982-07-01), None
patent: 126461/82 (1982-08-01), None
patent: 126462/82 (1982-08-01), None
patent: 126463/82 (1982-08-01), None
patent: 54/87 (1987-01-01), None
patent: 30462/88 (1988-02-01), None
patent: 218652/88 (1988-09-01), None
patent: 217950/82 (1992-08-01), None
patent: 197256/82 (1992-12-01), None
patent: 80548/94 (1994-03-01), None
patent: 80549/94 (1994-03-01), None
patent: 80550/94 (1994-03-01), None
patent: 95/25513 (1994-03-01), None
patent: 96/06825 (1996-03-01), None
Y. Nozawa et al., “Effects of Powder Roll Mixing to Cyclodextrin Molecular Complexation”, Funsai, vol. 36, 37-44 (1992).
N.M. Sanghavi, et al., “Solubilization of Glibenclamide with &bgr;-Cyclodextrin & Its Derivatives”, Drug Development And Industrial Pharmacy, 20(7), 1275-1283 (1994).
A. Marini, et al., “Thermoanalytical and Spectroscopic Characterization of &bgr;-Cyclodextrin/Ketoprofen Inclusion Complexes”, J. of Inclusion Phenomena and Molecular Recognition in Chemistry, 22, 221-234 (1995).
H. Hirai, et al., “Conformation of &bgr;-Cyclodextrin-Aromatic Carboxylate Inclusion Complex in Aqueous Solution”, Polymer J., vol. 28, No. 1, 91-94 (1996).
H.O. Ammar, et al., “Improvement of Some Pharmaceutical Properties of Drugs by Cyclodextrin Complexation”, Phamazie, 50, 408-410 (1995).
Kamoda Osamu
Mizoguchi Jun-ichi
Sato Seiji
Tamaki Eiji
Yanagi Toshiharu
Cook Rebecca
Corless Peter F.
Edwards & Angell LLP
O'Day Christine C.
Teikoku Chemical Industries Co., Ltd.
LandOfFree
Cyclohexane carbocyclic ester derivative and cyclodextrin... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Cyclohexane carbocyclic ester derivative and cyclodextrin..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Cyclohexane carbocyclic ester derivative and cyclodextrin... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2861860